Literature DB >> 26743054

[Porphyria cutanea tara].

H F Merk1,2.   

Abstract

Porphyria cutanea tara (PCT) has a prevelance of about 40 new diagnoses per 1 million people per year and is the most frequently occurring type of porphyria worldwide. Inhibition of the uroporphyrinogen decarboxylase (UROD) is the main cause of the disease, which can be the result of a heterozygous or homozygous mutation of the UROD gene; however, xenobiotics or other diseases may play an important role for the precipitation of the disease. Risk factors include alcohol, estrogen, iron overload, and hemochromatosis, hepatitis C or poisoning, e.g., with polyhalogenated aromatic compounds such as hexachlorobenzene. Signs and symptoms are blisters, skin fragility, erosions hyperpigmentation, sclerodermoid plaques. Therapy includes sun protection, prevention of risk factors, phlebotomy, and chloroquine.

Entities:  

Keywords:  Aryl-hydrocarbon-receptor; Chloroquine; Hexachlorobenzene; Sunscreening agents; Uroporphyrinogen decarboxylase

Mesh:

Substances:

Year:  2016        PMID: 26743054     DOI: 10.1007/s00105-015-3744-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  22 in total

1.  Porphyrins in urine as an indication of exposure to chlorinated hydrocarbons.

Authors:  J J Strik
Journal:  Ann N Y Acad Sci       Date:  1979-05-31       Impact factor: 5.691

2.  Sunitinib-induced pseudoporphyria.

Authors:  V Sanz-Motilva; A Martorell-Calatayud; B Llombart; C Requena; C Serra-Guillén; E Nagore; C Guillén; V Traves; O Sanmartín
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-05-12       Impact factor: 6.166

3.  Porphyria cutanea tarda occurring in a patient with renal failure, systemic lupus erythematosus and chronic hepatitis C infection treated with hemodialysis.

Authors:  P K Lee; I Abrahams; D R Bickers
Journal:  Cutis       Date:  1999-10

4.  Hexachlorobenzene alteration of benzo[a]pyrene metabolism in porphyric and non-porphyric rats.

Authors:  H Merk; K Bolsen; R Lissner; G Goerz
Journal:  IARC Sci Publ       Date:  1986

5.  HLA-A3 and -B7 in porphyria cutanea tarda.

Authors:  B M Kuntz; G Goerz; H Merk; G Strohmeyer; H T Brüster
Journal:  Tissue Antigens       Date:  1984-07

6.  Imatinib mesylate-induced pseudoporphyria in two children.

Authors:  Caroline Mahon; Diana Purvis; Stephen Laughton; Peter Bradbeer; Lochie Teague
Journal:  Pediatr Dermatol       Date:  2014-06-12       Impact factor: 1.588

Review 7.  Complex gene-chemical interactions: hepatic uroporphyria as a paradigm.

Authors:  Andrew G Smith; George H Elder
Journal:  Chem Res Toxicol       Date:  2010-04-19       Impact factor: 3.739

8.  Uroporphyrin I stimulation of collagen biosynthesis in human skin fibroblasts. A unique dark effect of porphyrin.

Authors:  G Varigos; J R Schiltz; D R Bickers
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

9.  Influence of chloroquine on the porphyrin metabolism.

Authors:  G Goerz; K Bolsen; H Merk
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

10.  Cutaneous manifestations of tetrachlorodibenzo-p-dioxin in children and adolescents. Follow-up 10 years after the Seveso, Italy, accident.

Authors:  R Caputo; M Monti; E Ermacora; G Carminati; C Gelmetti; R Gianotti; E Gianni; V Puccinelli
Journal:  J Am Acad Dermatol       Date:  1988-11       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.